The aim is to convert stem cells into beta cells and using them as an alternative to lifelong insulin therapy for patients with type 1 diabetes.It has teamed up with a new company OiDE Beta Revive set-up by Tokyo Institute of Technology, with financial backing from Mitsubishi UFJ Capital.

Tokyo Institute of Technology news release, January 10, 2019